Opinion: Experimental medical devices should be made available to patients

Patients should have the option to take more risks when seeking medical treatment, said Dr. Kevin Tracey in a Wall Street Journal column. Tracey, a neurosurgeon and CEO of the Feinstein Institute for Medical Research, argued that the FDA should not be solely responsible for approving potentially lifesaving treatments because existing institutional review boards and protocols already protect against many unsafe procedures. Ultimately, he said, the patient's satisfaction should determine success of a treatment option. Strict government regulations are a deterrent for entrepreneurs such as Sergey Brin and Larry Page of Google ($GOOG), who recently commented that healthcare was "a painful business to be in" when asked if they would consider entering the field, Tracey said. Post (sub. req.)

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.